Want to see MNPR full AI Analyst Report?
Top Page
Monopar Therapeutics Inc
(NASDAQ:MNPR)
Select Model
Select Model
Rating:47Neutral
Price Target:
$70.00
▼(-36.83% Downside)
Action:Reiterated
Date:09/27/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and ongoing cash burn, with an extremely negative TTM cash-flow figure in the provided data) and bearish technical momentum (price below key moving averages with negative MACD). Offsetting these risks, corporate events are a clear positive due to meaningful FDA-related milestones for ALXN1840, but they do not outweigh the current financial and trend headwinds.
Positive Factors
Low Financial Leverage
Extremely low leverage reduces financial risk and preserves flexibility while Monopar advances its clinical programs. With minimal debt obligations, the company has fewer fixed claims on cash and more capacity to direct available capital toward development and regulatory activities.
Negative Factors
No Commercial Revenue
Zero reported revenue shows that Monopar has not yet established a recurring product-based commercial business. Until a candidate is approved and launched, the company remains dependent on development progress rather than customer sales, leaving future funding and operating capacity tied to clinical and regulatory execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Extremely low leverage reduces financial risk and preserves flexibility while Monopar advances its clinical programs. With minimal debt obligations, the company has fewer fixed claims on cash and more capacity to direct available capital toward development and regulatory activities.
Read all positive factors
Monopar Therapeutics Inc (MNPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$474.21M
Dividend YieldN/A
Average Volume (3M)152.23K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS Growth29.73%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.34
Shares Outstanding6,712,172
10 Day Avg. Volume125,573
30 Day Avg. Volume152,229
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)3.51
Price to Sales (P/S)0.00
P/FCF Ratio-39.66
Enterprise Value/Market Cap1.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-35.50
Forecast
1Y Price Target
$129.29Price Target Upside16.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.98
Revenue Forecast (FY)N/A
Monopar Therapeutics Inc Business Overview & Revenue Model
Company Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; ...
How the Company Makes Money
Monopar Therapeutics does not have a stable, product-based commercial revenue stream because it is a clinical-stage drug developer and, as such, typically does not sell approved drugs. As a result, its ability to generate cash is primarily driven ...
Monopar Therapeutics Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
74
Positive
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -18.50M | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
| Net Income | -17.84M | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
Balance Sheet | ||||||
| Total Assets | 134.98M | 140.72M | 60.29M | 7.35M | 13.23M | 20.52M |
| Cash, Cash Equivalents and Short-Term Investments | 134.30M | 140.40M | 60.21M | 7.27M | 13.12M | 20.30M |
| Total Debt | 107.83K | 154.92K | 0.00 | 0.00 | 8.41K | 0.00 |
| Total Liabilities | 4.12M | 2.89M | 5.25M | 1.76M | 3.14M | 1.58M |
| Stockholders Equity | 130.85M | 137.83M | 55.04M | 5.59M | 10.09M | 18.94M |
Cash Flow | ||||||
| Free Cash Flow | -3.26B | -12.20M | -6.40M | -7.86M | -7.23M | -7.32M |
| Operating Cash Flow | -3.26B | -12.20M | -6.40M | -7.86M | -7.23M | -7.32M |
| Investing Cash Flow | 4.05B | -63.45M | -14.34M | 4.93M | -4.92M | 0.00 |
| Financing Cash Flow | -555.58M | 91.57M | 59.29M | 2.03M | 32.87K | 10.88M |
Monopar Therapeutics Inc Technical Analysis
Negative
110.82
Price Trends
95.58
Negative
94.85
Negative
77.09
Negative
Market Momentum
-6.67
Negative
30.74
Neutral
27.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MNPR, the sentiment is Negative. The current price of 110.82 is above the 20-day moving average (MA) of 76.42, above the 50-day MA of 95.58, and above the 200-day MA of 77.09, indicating a bearish trend. The MACD of -6.67 indicates Negative momentum. The RSI at 30.74 is Neutral, neither overbought nor oversold. The STOCH value of 27.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MNPR.
Monopar Therapeutics Inc Risk Analysis
Monopar Therapeutics Inc disclosed 77 risk factors in its most recent earnings report. Monopar Therapeutics Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Monopar Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $854.91M | -2.85 | -207.18% | ― | -7.27% | -48.89% | |
54 Neutral | $1.37B | -9.76 | -35.35% | ― | ― | 28.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $614.44M | -5.70 | -89.38% | ― | ― | -108.75% | |
49 Neutral | $1.08B | -3.64 | -159.32% | ― | ― | 2.95% | |
47 Neutral | $474.21M | -30.19 | -13.08% | ― | ― | 29.73% | |
44 Neutral | $505.53M | -5.16 | -38.46% | ― | -87.03% | -179.91% |
* Healthcare Sector Average
MNPR
Monopar Therapeutics Inc
70.65
-10.59
-13.04%
CTMX
CytomX Therapeutics
2.32
-1.04
-30.95%
KURA
Kura Oncology
9.61
-1.43
-12.95%
REPL
Replimune Group
11.46
2.13
22.83%
ORIC
Oric Pharmaceuticals
13.17
-0.23
-1.72%
CADL
Candel Therapeutics
8.03
2.63
48.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.